- Pfizer (NYSE:PFE) inks a multiyear agreement with Gilead Sciences (NASDAQ:GILD) to provide contract manufacturing services at its McPherson, KS facility to produce and supply COVID-19 antiviral Veklury (remdesivir).
- CEO Albert Bourla says the action is part of the company's five-point plan to commit resources to address the pandemic.
- Financial terms are not disclosed.
- PFE and GILD are both up 1% premarket on light volume.
